Aromatic amino acid metabolites as potential protein binding inhibitors in human uremic plasma.
Decreased binding of aromatic acidic drugs and endogenous metabolites to plasma proteins of patients with severe renal failure appears to be due to accumulation of unknown solutes. Both the warfarin and indole binding sites of albumin, the principal binding protein for these ligands, are affected. We used a large number of endogenous aromatic acids and synthetic congeners as displacers (a) better to characterize the chemical requirements for binding to each site and (b) to derive clues to the chemical structure of the undefined binding inhibitors in uremic plasma. 14C-tryptophan, 14C-warfarin and 14C-salicylate were used as bound ligands. Numerous indoles, quinolines and phenyl derivatives were moderate to strong displacers with several structural correlates. Increasing apolar side chain length enhanced displacing potency. A hydroxyl group at the 5 position of indoles and at the para position of phenyl derivatives severely reduced activity. The two ends of amphophilic molecules showed opposite requirements for displacement of tryptophan: the greater the polarity at the hydrophilic end, the greater the tryptophan displacing potency. Conversely, the greater the total hydrophobic mass of the remainder of the molecule, the more potent the inhibition of binding. The dipeptides l-tryptophyl-l-tryptophan and l-tryptophyl-l-phenylalanine were potent displacers. Computer-assisted analysis of warfarin binding in the presence of xanthurenic acid revealed inhibition by a mechanism other than simple competition, probably via a third albumin binding locus. We conclude that decreased binding in uremic plasma is most likely the summation effect of a number of retained aromatic acids, peptides, or both types of ligands.
D000596:Amino Acids / Q000378:metabolism*; D001798:Blood Proteins / Q000378:metabolism*; D006626:Hippurates / Q000494:pharmacology; D006801:Humans; D007211:Indoles / Q000378:metabolism; D007736:Kynurenic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D011485:Protein Binding; D011804:Quinolines / Q000494:pharmacology; D012459:Salicylates / Q000378:metabolism; D020156:Salicylic Acid; D012709:Serum Albumin / Q000378:metabolism; D013329:Structure-Activity Relationship; D014364:Tryptophan / Q000378:metabolism; D014511:Uremia / Q000097:blood*; D014859:Warfarin / Q000378:metabolism; D014977:Xanthurenates
D000596:Amino Acids; D001798:Blood Proteins; D006626:Hippurates; D007211:Indoles; D011804:Quinolines; D012459:Salicylates; D012709:Serum Albumin; D014977:Xanthurenates; C028330:xanthurenic acid; D014859:Warfarin; D014364:Tryptophan; D007736:Kynurenic Acid; D020156:Salicylic Acid; C030514:hippuric acid